Plasminogen activator inhibitor 1 (PAI-1) human
SIGMA/A8111 - recombinant, expressed in E. coli, ≥90% (SDS-PAGE)
Synonym: PAIE; PLANH1; Plasminogen activator inhibitor, β-migrating endothelial cell-derived type; Serpin E1 PAI-1; Serpine 1
CAS Number: 140208-23-7
MDL Number: MFCD01094930
Product Type: Chemical
SDS-PAGE Purity of Plasminogen activator inhibitor 1 (PAI-1) Human (Cat. No. A8111) was assessed on SDS-PAGE.
Mechanism of Plasminogen activator inhibitor 1 (PAI-1) human (Cat. No. A8111) inhibition
| assay | ≥90% (SDS-PAGE) |
| form | lyophilized powder |
| mol wt | ~43 kDa |
| Quality Level | 200  |
| recombinant | expressed in E. coli |
| shipped in | dry ice |
| solubility | water: 0.1 mL, clear, colorless |
| specific activity | ≥200,000 units/mg protein |
| storage temp. | −20°C |
| UniProt accession no. | P05121  |
| Analysis Note: | The product is the active human PAI-1 protein with a molecular weight of 43 kDa. |
| Application: | Plasminogen activator inhibitor 1 (PAI-1) human has been used: • as an inhibitor of pro-brain-derived neurotrophic factor (proBDNF) in radioimmunoprecipitation assay (RIPA) in peripheral blood and lymphocytes • to block plasmin activation in mice infected with C. albicans hyphae • to test its effect on neurite growth in neurons |
| Biochem/physiol Actions: | Plasminogen Activator Inhibitor 1 (PAI-1) protein belongs to the Serpin superfamily of serine protease inhibitors. It is the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), the activators of plasminogen and therefore inhibits the fibrinolysis process. PAI is involved in extracellular matrix remodeling and has been implicated in processes like angiogenesis, chemotaxis, ovulation, and embryogenesis. PAI-1 is present in increased levels in various disease states such as a number of cancer forms, obesity and the metabolic syndrome. |
| Biochem/physiol Actions: | Plasminogen activator inhibitor 1 (PAI-1), a member of the Serpin superfamily of serine protease inhibitors, is involved in extracellular matrix remodeling and implicated in processes like angiogenesis, chemotaxis, ovulation, and embryogenesis. |
| Biochem/physiol Actions: | Plasminogen activator inhibitor–1 (PAI -1) participates in mediating cellular senescence. It is upregulated during injury along with other tissue repair transcriptomes. Elevated levels of PAI-1 is regarded as one of the risks associated with myocardial infarction (MI). |
| General description: | Plasminogen activator inhibitor 1 (PAI-1) or serine protease inhibitor E1 (SERPINE1) gene is mapped to human chromosome 7q22.1. PAI-1 is produced in hepatocytes, endothelial cells, smooth muscle cells, megakaryocytes, and adipocytes. |
| Other Notes: | 1 unit irreversibly inhibits (100% inhibition) 1 unit of tissue plasminogen activator (tPA) under physiological conditions (neutral pH and 37 ºC). |
| Physical form: | Supplied as a lyophilized powder from a solution containing 0.5 M sodium chloride, 20 mM sodium acetate, and 50 mg/mL trehalose. |
| Preparation Note: | Reconstitute to 0.25 mg/ml with ultrapure water. The reconstituted product contains 0.25 mgP/mL in 0.5 M sodium chloride, 20 mM sodium acetate, and 50 mg/mL trehalose. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥90% (SDS-PAGE) |
| activity | specific activity: ≥200,000 units/mg protein |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |